On March 19, Lens Technology (06613) spent 22.59 million yuan to repurchase 760,300 A-shares.
LanSi Technology (06613) announced that on March 19, 2026, it spent 22.5909 million yuan to repurchase 760300 shares of Class A shares.
Lens Technology (06613) announced that on March 19, 2026, it will invest 22.59 million RMB to repurchase 760,300 A shares.
Related Articles
CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.
GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.
BRII-B(02137) released its annual performance, with a net loss attributable to shareholders of 223 million yuan, a year-on-year decrease of 56.19%.
CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit attributable to the parent company in 2025 was 1.647 billion yuan, a year-on-year increase of 1.18%.
GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.
BRII-B(02137) released its annual performance, with a net loss attributable to shareholders of 223 million yuan, a year-on-year decrease of 56.19%.
RECOMMEND
“Memory Price Surge” For 100 Days, Low‑End Smartphones Forced Into Decline
19/03/2026
Hong Kong Suddenly Becomes A New Destination For Middle Eastern Capital? Signs Of Increased Allocation Are Evident
19/03/2026
Memory Price Surge Persists For 100 Days, Forcing Low‑End Smartphones Toward Extinction
19/03/2026
